Tevogen Bio (NASDAQ:TVGN) PT Set at $4.20 by Fundamental Research

Tevogen Bio (NASDAQ:TVGN) has been assigned a $4.20 target price by investment analysts at Fundamental Research in a research report issued on Friday, BayStreet.CA reports. The brokerage currently has a “buy” rating on the stock. Fundamental Research’s target price suggests a potential upside of 480.75% from the stock’s current price.

Tevogen Bio Trading Down 0.9 %

Shares of TVGN stock opened at $0.72 on Friday. The firm has a 50 day moving average of $0.90. Tevogen Bio has a one year low of $0.66 and a one year high of $21.09.

Hedge Funds Weigh In On Tevogen Bio

A hedge fund recently bought a new stake in Tevogen Bio stock. Portland Global Advisors LLC bought a new position in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 5,782,209 shares of the company’s stock, valued at approximately $21,683,000. Tevogen Bio accounts for about 3.0% of Portland Global Advisors LLC’s investment portfolio, making the stock its 9th biggest position. Portland Global Advisors LLC owned 36.55% of Tevogen Bio at the end of the most recent reporting period.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.